Next Generation News and Research

RSS

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

Orthopaedic Surgeon implants first MIDLINE device at Valley Hospital

Just days after Centinel Spine's new STALIF MIDLINE Integrated Interbody Fusion system was unveiled at the annual meeting of the North American Spine Society (NASS), the first MIDLINE device has been successfully implanted by noted Orthopaedic Surgeon, John S. Thalgott, MD at Valley Hospital in Las Vegas, NV.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

DynaVox releases new additions to Vmax line of communication devices

DynaVox, the leading provider of speech generating devices and symbol-adapted special education software used to assist individuals in overcoming speech, language and learning challenges, today announced the release of two new additions to the Vmax™ line of communication devices, the Vmax+ High Performance and the Vmax+ Battery Efficiency.

21 Oct 2010

Researchers investigate reverse zoonosis in marine invertebrate

The spread of lethal diseases from animals to humans has long been an issue of great concern to public health officials. But what about diseases that spread in the other direction, from humans to wildlife. A multidisciplinary team of researchers at the University of Georgia has just been awarded a five-year $2 million Ecology of Infectious Diseases grant from the National Science Foundation and National Institutes of Health to study the first known case of such a "reverse zoonosis" that involves the transmission of a human pathogen to a marine invertebrate, elkhorn coral.

21 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

New mechanism controlling transmission of abnormal signal at origin of several cancers identified

Researchers at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al have identified a new mechanism controlling the transmission of an abnormal signal at the origin of several cancers. In an article published in the journal Cell, Marc Therrien's team explains the recent discovery of a protein complex that controls the RAS/MAPK signalling pathway, responsible for some of the deadliest cancers, including pancreatic, colon and lung cancers, and melanomas.

21 Oct 2010

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ profiling service and immunoSEQ Analyzer bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

21 Oct 2010

FDA purchases AB SCIEX QTRAP 5500 Systems for analysis of the U.S. food supply

AB SCIEX, a global leader in life science analytical technologies, today announced that the U.S. Food and Drug Administration has purchased eight of the company's AB SCIEX QTRAP® 5500 Systems for analysis of the U.S. food supply. These mass spectrometry systems will be deployed at FDA headquarters and across seven field laboratories. This supports government initiatives to help ensure food safety.

20 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

New model for rural clinics in underserved areas

The University of Maryland Dental School Clinic, Perryville is a new model for rural clinics in underserved areas across the country, says Christian S. Stohler, DMD, DrMedDent, dean of the Dental School in Baltimore.

20 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

Xenogenics acquires Ideal BioStent assets

MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.

19 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

HOYA ConBio™, a global leader in dental and aesthetic lasers, today announced an extension of its sponsorship agreement with the Las Vegas Institute for Advanced Dental Studies (LVI), the pioneer in live-patient, post-graduate dental training. The agreement ensures that VersaWave™ and DioDent™ Micro 980 lasers will continue to be featured at LVI's advanced teaching facilities through 2013.

19 Oct 2010

UC awarded $2.1 million technology award to develop next generation brain monitors

The U.S. Department of Defense has awarded researchers at the University of Cincinnati (UC) a $2.1 million Advanced Technology/Therapeutic Development Award to develop the next generation of brain monitors.

19 Oct 2010

New research coalition to design first human trial of mosaic HIV vaccine candidate

Duke University Medical Center vaccine experts have assembled an international team of investigators to design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity

19 Oct 2010

PharmaTrust to launch third generation MedCentre remote dispensing system

PharmaTrust is launching the next generation of the MedCentre remote dispensing system with world-class features that redefine and take remote dispensing services to the next level. The MedCentre is a modular, scalable solution designed to meet both patients' need for convenience and counseling and healthcare professionals' responsibility to deliver the highest level of care.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Next Generation News and Research

Biogen, Genentech announce new structure of anti-CD20 collaboration

Orthopaedic Surgeon implants first MIDLINE device at Valley Hospital

Dicerna secures $4 million in second closing of Series B equity financing

DynaVox releases new additions to Vmax line of communication devices

Researchers investigate reverse zoonosis in marine invertebrate

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

LSUHSC receives NIH grant for research on cancer and infectious diseases

New mechanism controlling transmission of abnormal signal at origin of several cancers identified

New immunoSEQ bioinformatics software platform helps monitor adaptive immune system

FDA purchases AB SCIEX QTRAP 5500 Systems for analysis of the U.S. food supply

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

New model for rural clinics in underserved areas

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Xenogenics acquires Ideal BioStent assets

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

HOYA ConBio's dentistry lasers to be featured at LVI's teaching facilities through 2013

UC awarded $2.1 million technology award to develop next generation brain monitors

New research coalition to design first human trial of mosaic HIV vaccine candidate

PharmaTrust to launch third generation MedCentre remote dispensing system

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News